RT Journal Article
SR Electronic
T1 Systems immunology reveals the molecular mechanisms of heterogeneous influenza vaccine response in the elderly
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.10.23292445
DO 10.1101/2023.07.10.23292445
A1 Kumar, Saumya
A1 Zoodsma, Martijn
A1 Nguyen, Nhan
A1 Pedroso, Rodrigo
A1 Trittel, Stephanie
A1 Riese, Peggy
A1 Botey-Bataller, Javier
A1 Zhou, Liang
A1 Alaswad, Ahmed
A1 Arshad, Haroon
A1 Netea, Mihai G.
A1 Xu, Cheng-Jian
A1 Pessler, Frank
A1 Guzmán, Carlos A.
A1 Graca, Luis
A1 Li, Yang
YR 2023
UL http://medrxiv.org/content/early/2023/07/12/2023.07.10.23292445.abstract
AB Vaccination-induced protection against influenza is greatly diminished and increasingly heterogeneous with age. We investigated longitudinally (up to five timepoints) a cohort of 234 elderly influenza vaccinees across two independent seasons including up to six modalities (multi-omics and immunological parameters). System-level analyses revealed responders exhibited time-dependent changes attributed to a productive vaccine response across all omics layers whereas non-responders did not follow such dynamics, suggestive of systemic dysregulation. Through multi-omics integration, we identified key metabolites and proteins and their likely role in immune response to vaccination. High pre-vaccination IL-15 concentrations negatively associated with antibody production, further supported by experimental validation in mice revealing an IL-15-driven NK-cell axis with a suppressing role on antibody production. Finally, we propose certain long-chain fatty acids as modulators of persistent inflammation in non-responders. Our findings highlight the potential for stratification of vaccinees and open avenues for possible pharmacological interventions to enhance vaccine responses.HIGHLIGHTSPre-vaccination pro-inflammatory status impedes vaccine responsiveness in the elderly.Multi-omics integration reveals key molecules involved in vaccine response.High pre-vaccination concentrations of IL-15 suppresses vaccine response through NK cell activation.Certain long-chain fatty acids may act as modulators against chronic inflammation and are potential targets to improve vaccine response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by an ERC starting Grant (948207), a Radboud University Medical Centre Hypatia Grant (2018) and the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) under Germany's Excellence Strategy - EXC 2155 project number 390874280 to YL and iMed, the Helmholtz Associations Cross Programme Initiative on Personalized Medicine, to CAG and FP. C-JX was supported by a Helmholtz Initiative and Networking Fund (1800167). MGN was supported by an ERC Advanced Grant (833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research. LG research was supported by grants HR22-00741 (la Caixa Foundation), and 2022.04903.PTDC (Fundacao para a Ciencia e Tecnologia Portugal). This project was also partly supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 955321Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Hannover Medical School gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw data and code will be made available upon publication. Datasets are fully available for reviewers.